Cytarabine

AVEO Reports First Quarter 2019 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 9, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Other Health, Professional services, Banking, Finance, Cars, Clinical medicine, Cancer, Hatchbacks, Sedans, Subcompact cars, Oncology, Ficlatuzumab, Chevrolet Aveo, 7+3, Asco, Cytarabine

AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2019 and provided a business update.

Key Points: 
  • AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2019 and provided a business update.
  • Announced Positive Results from Phase 1b Ficlatuzumab-Cytarabine Trial (CyFi) in Patients with Relapsed and Refractory AML.
  • Presented Topline Results from TIVO-3 in an Oral Presentation at the 2019 ASCO Genitourinary Cancers Symposium and Announced Updated NDA Timing.
  • While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

CMS Grants New Technology Add-On Payment to Vyxeos® (daunorubicin and cytarabine) Liposome for Injection

Retrieved on: 
Friday, August 3, 2018
Medicine, RTT, Clinical medicine, Cancer, Medical terminology, Healthcare in the United States, Healthcare reform in the United States, 7+3, Medicare, Cytarabine, Daunorubicin, Diagnosis-related group

The Vyxeos NTAP will support Medicare beneficiaries' access to Vyxeos when they are treated in certain inpatient hospital settings.

Key Points: 
  • The Vyxeos NTAP will support Medicare beneficiaries' access to Vyxeos when they are treated in certain inpatient hospital settings.
  • The NTAP payment is in addition to the diagnosis-related group (MS-DRG)-based reimbursement that hospitals receive under the Medicare HospitalInpatient Prospective Payment System (IPPS).
  • Based on evaluation of the new technology add-on payment application and consideration of the public comments we received, we have determined that Vyxeos meets all of the criteria for approval for new technology add-on payments.
  • Vyxeos (daunorubicin and cytarabine) liposome for injection 44mg/100mg is a liposome formulation of a fixed combination of daunorubicin and cytarabine for intravenous infusion.1 Vyxeos is indicated for the treatment of adults with newly-diagnosed t-AML or AML-MRC.

CMS Grants New Technology Add-On Payment to Vyxeos® (daunorubicin and cytarabine) Liposome for Injection

Retrieved on: 
Friday, August 3, 2018
Medicine, RTT, Clinical medicine, Cancer, Medical terminology, Healthcare in the United States, Healthcare reform in the United States, 7+3, Medicare, Cytarabine, Daunorubicin, Diagnosis-related group

The Vyxeos NTAP will support Medicare beneficiaries' access to Vyxeos when they are treated in certain inpatient hospital settings.

Key Points: 
  • The Vyxeos NTAP will support Medicare beneficiaries' access to Vyxeos when they are treated in certain inpatient hospital settings.
  • The NTAP payment is in addition to the diagnosis-related group (MS-DRG)-based reimbursement that hospitals receive under the Medicare HospitalInpatient Prospective Payment System (IPPS).
  • Based on evaluation of the new technology add-on payment application and consideration of the public comments we received, we have determined that Vyxeos meets all of the criteria for approval for new technology add-on payments.
  • Vyxeos (daunorubicin and cytarabine) liposome for injection 44mg/100mg is a liposome formulation of a fixed combination of daunorubicin and cytarabine for intravenous infusion.1 Vyxeos is indicated for the treatment of adults with newly-diagnosed t-AML or AML-MRC.

Tolero Pharmaceuticals Presents Clinical Data for Investigational Agent Alvocidib in Patients with Relapsed Refractory MCL-1-Dependent AML at EHA 2018

Retrieved on: 
Friday, June 15, 2018
Cancer, Clinical medicine, RTT, Medicine, Orphan drugs, Protein kinase inhibitors, 7+3, Alvocidib, Acute myeloid leukemia, Cytarabine, Sumitomo Dainippon Pharma, Mitoxantrone

Alvocidib is also being evaluated in Zella 101, a Phase I clinical study evaluating the maximum tolerated dose, safety and clinical activity of alvocidib in combination with (7+3) in newly diagnosed patients with AML ( NCT03298984 ).

Key Points: 
  • Alvocidib is also being evaluated in Zella 101, a Phase I clinical study evaluating the maximum tolerated dose, safety and clinical activity of alvocidib in combination with (7+3) in newly diagnosed patients with AML ( NCT03298984 ).
  • Tolero Pharmaceuticals is based in the United States and is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan.
  • Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.
  • Phase II Study Incorporating A Novel Bh3-Profiling Biomarker Approach Of Alvocidib Followed By Cytarabine And Mitoxantrone In Relapsed/Refractory Acute Myeloid Leukemia (AML).